Wockhardt
-
{
- All
- News
- Videos
-
US FDA Approval For Zaynich Puts Wockhardt's Innovation Bet To The Test
Zaynich, approved for complicated urinary tract infections and pyelonephritis, is aimed at treating infections caused by drug-resistant bacteria — an area where doctors globally are facing shrinking treatment options as antimicrobial resistance rises.
-
93% Crash To 1000% Surge: How A Rare Drug Discovery In A Rs 82,000 Crore Market Rescued An Indian Pharma Giant
A single discovery is at the centre of this turnaround — here’s how it unfolded.
-
'Expect Large Revenue': Wockhardt Ready To Break Out Of Current Range After Historic USFDA Nod For Zaynich
Wockhardt is confident about breaking out of the current Rs 3,000-3,500 crore revenue range, even stating that FY28 could be a pivotal year for the company.
-
Wockhardt Shares Extend Gains — Here's Why The Stock Has Been Rising
The sharp rally in Wockhardt shares come on the back of Monday's development, as the company confirmed USFDA approval for Zaynich antibiotic.
-
Wockhardt Shares Jump More Than 11% After Landmark Acceptance — Here's What You Need To Know
The approval from USFDA marks a pivotal moment not just for Wockhardt but for Indian pharma, as it highlights the ability of Indian pharma companies to innovate.
-
Wockhardt Rebounds From Friday's Slump; Stock Surges 9% — Here's Why
Wockhardt Pharma was one of the worst hit pharma stocks in India following Trump's announcement, falling more than 9% in two trading sessions.
-
Buy, Sell Or Hold: MCX, ABB, Wockhardt, Zydus Life, Shilpa Medicare — Ask Profit
Analysts also offered insights on the share price of PNB Housing Finance.
-
Wockhardt Eyes ‘Healthy Bottom Line’ In Coming Quarters Amid US Tariff Concerns
The company recently announced its exit from the loss-making US generics business.
-
Wockhardt Q1 Results: Loss Widens To Rs 108 Crore
Wockhardt's revenue from operations in the quarter was marginally down at Rs 738 crore against Rs 739 crore in the year-ago period.
-
Wockhardt To Focus On Drug Discovery And Biologics: Chairman Khorakiwala On Exiting US Generics Business
The leading pharma company’s US generics business incurred a loss of $8 million in FY25.
-
Dealer Desk Buzz: FIIs, HNIs Active In Paytm, Dabur, Anant Raj, Coforge
Paytm saw foreign institutional investor interest, while Anant Raj drew accumulation from a large family office, according to dealer desk sources.
-
Buy, Sell Or Hold: Wockhardt, Oswal Pumps, JSW Infra, IRFC, Zee, PNB — Ask Profit
Sundar Kewat of Ashika Institutional Equity and Avinash Gorakshakar of Profitmart Securities provide insights.
-
Buy, Sell Or Hold: Mazagon, Cochin Shipyard, Infosys, Wockhardt, ONGC, Piramal Pharma — Ask Profit
Analysts also shared insights on share prices of Bajaj Housing Finance and Suzlon Energy.
-
Wockhardt Not To Face Significant Impact Of US Tariffs, Says Chairman Khorakiwala
Wockhardt’s exposure to the US market is just 5%, with plans to exit the generic business soon.
-
Buy, Sell Or Hold: Trent, L&T, Titan, Infosys, Tata Motors, Bajaj Finserv, Bharat Forge — Ask Profit
Analysts also shared insights for short-term and long-term investors on the share prices of Wockhardt and Suzlon Energy.
-
US FDA Approval For Zaynich Puts Wockhardt's Innovation Bet To The Test
Zaynich, approved for complicated urinary tract infections and pyelonephritis, is aimed at treating infections caused by drug-resistant bacteria — an area where doctors globally are facing shrinking treatment options as antimicrobial resistance rises.
-
93% Crash To 1000% Surge: How A Rare Drug Discovery In A Rs 82,000 Crore Market Rescued An Indian Pharma Giant
A single discovery is at the centre of this turnaround — here’s how it unfolded.
-
'Expect Large Revenue': Wockhardt Ready To Break Out Of Current Range After Historic USFDA Nod For Zaynich
Wockhardt is confident about breaking out of the current Rs 3,000-3,500 crore revenue range, even stating that FY28 could be a pivotal year for the company.
-
Wockhardt Shares Extend Gains — Here's Why The Stock Has Been Rising
The sharp rally in Wockhardt shares come on the back of Monday's development, as the company confirmed USFDA approval for Zaynich antibiotic.
-
Wockhardt Shares Jump More Than 11% After Landmark Acceptance — Here's What You Need To Know
The approval from USFDA marks a pivotal moment not just for Wockhardt but for Indian pharma, as it highlights the ability of Indian pharma companies to innovate.
-
Wockhardt Rebounds From Friday's Slump; Stock Surges 9% — Here's Why
Wockhardt Pharma was one of the worst hit pharma stocks in India following Trump's announcement, falling more than 9% in two trading sessions.
-
Buy, Sell Or Hold: MCX, ABB, Wockhardt, Zydus Life, Shilpa Medicare — Ask Profit
Analysts also offered insights on the share price of PNB Housing Finance.
-
Wockhardt Eyes ‘Healthy Bottom Line’ In Coming Quarters Amid US Tariff Concerns
The company recently announced its exit from the loss-making US generics business.
-
Wockhardt Q1 Results: Loss Widens To Rs 108 Crore
Wockhardt's revenue from operations in the quarter was marginally down at Rs 738 crore against Rs 739 crore in the year-ago period.
-
Wockhardt To Focus On Drug Discovery And Biologics: Chairman Khorakiwala On Exiting US Generics Business
The leading pharma company’s US generics business incurred a loss of $8 million in FY25.
-
Dealer Desk Buzz: FIIs, HNIs Active In Paytm, Dabur, Anant Raj, Coforge
Paytm saw foreign institutional investor interest, while Anant Raj drew accumulation from a large family office, according to dealer desk sources.
-
Buy, Sell Or Hold: Wockhardt, Oswal Pumps, JSW Infra, IRFC, Zee, PNB — Ask Profit
Sundar Kewat of Ashika Institutional Equity and Avinash Gorakshakar of Profitmart Securities provide insights.
-
Buy, Sell Or Hold: Mazagon, Cochin Shipyard, Infosys, Wockhardt, ONGC, Piramal Pharma — Ask Profit
Analysts also shared insights on share prices of Bajaj Housing Finance and Suzlon Energy.
-
Wockhardt Not To Face Significant Impact Of US Tariffs, Says Chairman Khorakiwala
Wockhardt’s exposure to the US market is just 5%, with plans to exit the generic business soon.
-
Buy, Sell Or Hold: Trent, L&T, Titan, Infosys, Tata Motors, Bajaj Finserv, Bharat Forge — Ask Profit
Analysts also shared insights for short-term and long-term investors on the share prices of Wockhardt and Suzlon Energy.
